MiRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma

Jisce R. Puik, Laura L. Meijer, Tessa Y.S. Le Large, Mireia Mato Prado, Adam E. Frampton, Geert Kazemier, Elisa Giovannetti*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Cholangiocarcinoma (CCA) is a lethal malignancy originating from the biliary tract epithelium. Most patients are diagnosed at an advanced stage. Even after resection with curative intent, prognosis remains poor. Previous studies have reported the evolving role of miRNAs as novel biomarkers in cancer diagnosis, prognostication and chemotherapy response. Various miRNAs, such as miR-21, miR-26, miR-122 and miR-150, have been identified as possible blood-based biomarkers for noninvasive diagnosis of CCA. Moreover, epithelial-mesenchymal transition (EMT)- and angiogenesis-associated miRNAs have been implicated in tumor cell dissemination and are able to determine clinical outcome. In fact, miRNAs involved in cell survival might even determine chemotherapy response. This review provides an overview of known miRNAs as CCA-specific biomarkers.

Original languageEnglish
Pages (from-to)1343-1358
Number of pages16
JournalPharmacogenomics
Volume18
Issue number14
DOIs
Publication statusPublished - 1 Sep 2017

Cite this